Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

This study revealed an association between elevated hepatic histamine levels and erythropoietic protoporphyria progression.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

This is an important and solid study that examines the role of TFAM, a protein that helps maintain mtDNA, in mtDNA mutator mice. The authors have demonstrated that TFAM's counteractive role in mtDNA ...

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...